Reuters
Published Jan 03, 2021 01:55PM ET
BRASILIA (Reuters) - Brazil's health regulator Anvisa said late on Saturday it had approved the import of 2 million doses of the COVID-19 vaccine developed by AstraZeneca (NASDAQ:AZN) and the University of Oxford, although the jab is not yet approved for use in the country.
Anvisa said it approved the importation request from federal government-affiliated biomedical center Fiocruz on Thursday.
Importing the doses prior to approval will enable vaccination to begin as soon as Anvisa okays its use, the regulator said. Brazil has yet to approve any vaccine.
Fiocruz will apply for emergency use of the vaccine by Wednesday, its president, Nísia Trindade, said last week.
Brazil has recorded the second-deadliest outbreak of COVID-19 after only the United States. South America's largest country has the third highest tally of coronavirus cases, with the health ministry registering more than 7.7 million, after the United States and India.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.